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Although a large proportion of patients with osteoarthritis (OA) show inﬂammation in their affected
joints, the pathological role of inﬂammation in the development and progression of OA has yet to be
clariﬁed. Glutamate is considered an excitatory amino acid (EAA) neurotransmitter in the mammalian
central nervous system (CNS). There are cellular membrane glutamate receptors and transporters for
signal input modulation and termination as well as vesicular glutamate transporters (VGLUTs) for signal
output through exocytotic release. Glutamate been shown to mediate intercellular communications in
bone cells in a manner similar to synaptic transmission within the CNS. Glutamate-mediated events may
also contribute to the pathogenesis and ongoing processes of peripheral nociceptive transduction and
inﬂammation of experimental arthritis models as well as human arthritic conditions. This review will
discuss the differential roles of glutamate signaling and blockade in peripheral neuronal and non-
neuronal joint tissues, including bone remodeling systems and their potentials to impact OA-related
inﬂammation and progression. This will serve to identify several potential targets to direct novel ther-
apies for OA. Future studies will further elucidate the role of glutamate in the development and pro-
gression of OA, as well as its association with the clinical features of the disease.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Role of excitatory amino acids in peripheral nociceptive
transduction
Osteoarthritis (OA), a complex disease of the whole joint, is
characterized by structural degradation of the articular cartilage,
peri-articular bone, synovial joint lining, and adjacent supporting
connective tissue elements. OA manifests as joint pain and loss of
joint function and currently has no satisfying treatments. Although
a large of proportion of patients with OA show inﬂammation in
their affected joints, the pathological role of inﬂammation in OA
development and progression has yet to be clariﬁed. Glutamate is
thought to be an excitatory amino acid (EAA) neurotransmitter in
the mammalian central nervous system (CNS). Evidence that: Y.-H. Jean, Department of
gtung, No. 60, Da-Lan Road,
886-8-7380574.
n).
ternational. Published by Elsevier Lglutamatergic signaling is also functional in non-neuronal tissues
outside the CNS such as the pancreas, skin, and bone is accumu-
lating in the literature1,2. Glutamate may be one of the endogenous
autocrine/paracrine factors that play a role in intercellular com-
munications within the bone-related cells3,4. In bone, several pos-
sibilities of glutamate origin are conceivable. Both sympathetic and
sensory nerve ﬁbers innervate into bone, while glutamatergic
innervation is distributed even in bone5,6. Involvement of EAA in
peripheral nociceptive transduction has also been reported in an-
imal models of acute arthritis7. In a kaolin/carrageenan-induced
arthritis model in rats, the expected increase in synovial ﬂuid (SF)
glutamate levels was blocked by pretreatment with intra-articular
lidocaine, which decrease neurotransmitter release from the
peripheral neuronal endings in the joint in response to injury8.
Indeed, glutamate may act as a more widespread “cytokine” rather
than as a “neurotransmitter” and inﬂuence a variety of cellular
activities in different tissues1,2.
Glutamate is highly involved in both pain and metabolic
pathways9e12. Beyond the physiological roles of glutamate in
joint tissues, growing evidence in clinical and experimentaltd. All rights reserved.
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contribute to the pathogenesis of human arthritic conditions13. Our
group determined that glutamate and aspartate levels were
signiﬁcantly increased in the microdialysates of anterior cruciate
ligamentetransected (ACLT) knee joints in rats, suggesting a role of
EAA in the acute and ongoing progressive processes of soft tissue
injuries that impact early OA development14. Additionally, Alfred-
son et al.15, reported an increase in glutamate levels in the tendon
dialysate samples derived from in patients with painful chronic
Achilles tendinosis. Franklin et al.16 reported that glutamate and the
glutaminergic system may play key roles in painful human supra-
spinatus tendon tears and importantly, previous studies have
demonstrated signiﬁcantly increased SF glutamate and aspartate
levels in patients with active arthropathies17,18.
Elevated levels of glutamate in SF dialysates have been shown to
be relevant to increased swelling and sensitization to thermal
hyperalgesia in experimental (inﬂammatory or injury-based)
arthritis models14. In previous in vitro studies, local glutamate can
bind and activate peripheral receptors on local osteocytes, chon-
drocytes, and synoviocytes to enhance local inﬂammation and
pathologies19e24. Signiﬁcant associations between EAA and in-
ﬂammatorymediators have been demonstrated in the SF of patients
with active arthropathies, including OA18. From clinical samples, SF
glutamate levels correlated with increased SF levels of inﬂamma-
tory mediators such as tumor necrosis factor-a (TNF-a), regulated
on activation normal T-cell expressed and secreted (RANTES), and
interleukin-8 (IL-8) in the SF of patients with active inﬂammatory
arthropathies, such as RA, acute gout and symptomatic OA18,19.
In our previous studies, injections of hyaluronic acid fromweeks
8e12 in ACLT rat knees slowed the progression of OA related
changes and was accompanied by decreased SF-microdialysate
glutamate levels25.
The excess glutamate released within inﬂamed tissues is likely
derived from a variety of neuronal and non-neuronal sources.
Among the sources investigated previously are nerves, lympho-
cytes, macrophages, synoviocytes, osteoblasts, osteoclasts and
chondrocytes8,13,19,26, mast cells27, platelets28, neutrophils29, and
ﬁbroblasts or Schwann cells30,31. OA-associated pain may result at
least in part from glutamate release from the axons innervating the
inﬂamed region32. A vast number of potential mediators have been
shown to be associated with both clinically and experimentally
induced arthritic animals, also originating from multiple potential
sources. Outlined below, we will address potential signaling sys-
tems in which glutamate may play a role as an extracellular signal
mediator and clarify its role as an inﬂammatory mediator in the
bones and joints of individuals with OA.
Expression and function of EAA glutamate receptors,
glutamate transporters, and vesicular glutamate transporters
(VGLUTs) in bone and joints
Glutamate receptors
The actions of extracellular glutamate are mediated by mem-
branous receptors, which can be divided into ionotropic (iGluRs)
and metabotropic (mGluRs) receptors, according to their differen-
tial intracellular signal transduction mechanisms and molecular
homologies33.
The former are further classiﬁed into N-methyl-D-aspartate
(NMDA), DL-a-amino-3-hydroxy-5-methylisoxasole-4-propionate
(AMPA), and kainate (KA) subtypes according to their sequential
similarities and responsiveness to different agonists and antago-
nists34, whereas the latter is further divided into three distinct
subtypes with seven transmembrane domains, including group I
(mGluR1 and mGluR5), group II (mGluR2 and mGluR3), and groupIII (mGluR4, mGluR6, mGluR7, and mGluR8), according to exoge-
nous agonists and intracellular second messengers35. NMDA re-
ceptors are multimeric complexes that consist of NR1 subunits and
one of four NR2 subunits (NR2A-D)36. The NMDA receptor subunit 1
(NR1) is considered an essential component of all functional NMDA
receptors37. Increased phosphorylation of NR1 (p-NR1), which oc-
curs via intracellular signaling pathways, has been recognized as an
important mechanism contributing to the regulation of NMDA re-
ceptor function38. Various components of the glutamate receptors
were recently detected in cartilage cells. For instance, rat costal
chondrocytes express mRNA for NMDA and non-NMDA re-
ceptors39. Moreover, using immunohistochemistry and reverse
transcription polymerase chain reaction (RT-PCR) techniques, the
NMDAR1 and NMDAR2A subunits of NMDA receptors were both
found to express in normal and OA chondrocytes40. Moreover, in
mammalian bone, NMDA receptors are also expressed in osteo-
blasts and osteoclasts as revealed by RT-PCR, in situ hybridization,
immunohistochemistry, and electrophysiology41,42.
NMDA, AMPA, KA, and metabotropic glutamate receptor sub-
types 1, 4, and 5 (mGlu1, mGlu4, and mGlu5) were shown to
mediate pain in the arthritic joint9,10. Lawand et al.43 showed that
NMDA antagonists injected into an inﬂamed knee decreased blood
ﬂow and swelling in the periarticular regions, while Zhang et al.11
demonstrated a role of NMDA receptors in the induction of
arthritic joint pain. Glutamate and its receptor agonists were also
reported to induce TNF-a production in synovial cells, which
further upregulated chemokine and cytokine production in pri-
mary synoviocyte cultures from a patient with RA18. Flood et al.
indicate that the activation of NMDA and KA glutamate receptors
on human synoviocytes may lead to joint destruction by enhancing
IL-6 expression21. NMDA glutamate receptor antagonists also
decreased proliferation and inhibited IL-1beinduced increases in
cyclooxygenase (COX)-2, IL-6, and matrix metalloproteinase 3
(MMP3) mRNA expression in rat chondrocytes13.
Free radicals are intermediate products in cyclooxygenase
(COX)-mediated prostaglandin (PG) synthesis. PG products pro-
duced in the COX pathway stimulated Ca2þ-dependent glutamate
release in cultured astrocytes44 and thus were shown to be
involved in NMDA receptor-mediated glutamate excitotoxicity45.
Our previous study in rats demonstrated that the selective COX-2
inhibitor parecoxib (Dynastat; Pﬁzer, USA) reduced OA model
progression. The alleviation of synovitis and cartilage injury was
associated with concomitantly decreased glutamate and aspartate
levels in the knee joint dialysates after intra-articular parecoxib
treatment46.
Glutamate has also been shown to suppress the proliferation of
mesenchymal stem cells47, which have the potential to differentiate
into chondrocytes. The differential expression and signaling of
NMDA receptor subunits in chondrocytes may promote OA24, by
several contributory mechanisms including mediating inﬂamma-
tory mediator responses and blocking chondrocyte development13.
The above support that glutamate receptor activation could be a
key regulator in peripheral pain12, cytokine and MMP release,
chondrocyte and synoviocyte proliferation47,48, and immune re-
actions49. Conversely, glutamate receptor antagonists could
potentially provide or complement novel therapies with multi-
modal activities against arthritis and OA symptoms.
Glutamate receptor activation has also been studied in bone
physiology. Both ionotropic and metabotropic glutamate receptors
are reportedly functional in osteoblasts22 and osteoclasts50, while
antagonists to these receptors can modify bone cell pheno-
types42,50. Functional NMDA receptors have been reported in
several classes of osteocytes and bone cells, including rat and
human osteoblasts and osteoclasts, MG-63 osteosarcoma cells,
and bone marrow megakaryocytes42,51. Osteoblasts constitutively
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of AMPA receptors as well as the KA1 and KA2 subunits of KA re-
ceptors52. AMPA receptors have been demonstrated to modulate
the exocytotic release of glutamate from cultured osteoblasts3,4.
Moreover, AMPA receptor activation increased bone formation and
mineralization53, whereas AMPA receptor antagonists reduced
bone mass54 by inhibiting osteoblast activity and mineralization53.
Dizocilpine (MK-801), a non-competitive NMDA receptor
antagonist, diminished increased alkaline phosphatase activity and
Ca2þ accumulation as well as osteocalcin expression during cellular
maturation through the inhibition of core binding factor a-1
expression in cultured calvarial rat osteoblasts41. Flood et al.
demonstrated that MK-801 in RA ﬁbroblast-like synoviocytes
induced increased MMP-2 release, whereas non-NMDA ionotropic
glutamate receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione (NBQX) inhibited IL-6 production;
this ﬁnding suggested that glutamate receptor antagonists may
multimodally inﬂuence RA pathology21. NBQX (AMPA/KA antago-
nist) may also target AMPA and KA glutamate receptors expressed
by synoviocytes55 and chondrocytes56 to regulate receptor activator
of nuclear factor kappa-B ligand (RANKL) or directly inhibit osteo-
clast activity57. Moreover, a single intra-articular injection of NBQX
alleviated inﬂammation, pain, and joint degeneration in rat
adjuvant-induced arthritis58.
Bondok and El-Hady showed that intra-articular magnesium
reduces the postoperative analgesic requirement of patients after
arthroscopic knee surgery59. Zhang et al.60 reported that IL-1 re-
ceptor antagonist (Anakinra, Amgen, CA) decreased bone cancer
pain and decreased p-NR1 expression and nociceptive behaviors,
suggesting that effective decrease of spinal p-NR1 could impact
pain levels. Magnesium deﬁciency upregulates IL-1a and IL-6,
which are pleiotropic cytokines implicated in acute phase re-
sponses and inﬂammation61. NMDA receptor channels are highly
permeable to Ca2þ and sensitive to blockade by Mg2þ in a voltage-
dependent manner62. In a collagenase induced experimental model
of OA, our group demonstrated increased p-NR1 expression in the
articular cartilage. Our results showed that local intra-articular
administration of MgSO4: (1) inhibited p-NR1 expression and
chondrocyte apoptosis; (2) attenuated the development of OA; and
(3) concomitantly reduced nociceptive behaviors63. The classiﬁca-
tion of glutamate receptors and protein expression in bone cells
and chondrocytes is shown in Table I.
The present extensive review of the literature indicates a role for
glutamate signaling in OA disease, but it remains unclear in whichTable I
Classiﬁcation of glutamate receptors and protein expression in bone cells and chondrocy
Glutamate receptor Protein expression
Oste
Ionotropic (iGluR) NMDA NR1 NR1
(NR1A-G)
NR2
(NR2A-D)
NR3(A,B)
Kainate KA1
KA2
AMPA GluR5-GluR7
GluR1-GluR4 GluR
Metabotropic (mGluR) I mGluR1
mGluR5
II mGluR2
mGluR3
III mGluR4
mGluR6
mGluR7
mGluR8
NR2B*: expression of NR2B only in OA but not in normal chondrocytes.joint tissues and at which stage of progressive OA this role is most
pronounced. The role glutamate in OA development and progres-
sion remains amystery and further investigation is needed to better
elucidating the role of glutamate signaling in the stage and path-
ogenesis of OA.
Glutamate transporters
Extracellular glutamate levels are regulated by high-afﬁnity
excitatory amino acid transporters (EAATs)64. EAATs are known to
be responsible for maintaining the homeostasis of the extracellular
glutamate concentration by protecting neurons against detrimental
overstimulation of glutamatergic receptors65. EAATs are classiﬁed
into ﬁve different subtypes: glutamate aspartate transporter
(GLAST; EAAT1), glutamate transporter-1 (GLT-1; EAAT2), excit-
atory amino acid carrier-1 (EAAC1) (EAAT3), EAAT4, and EAAT564.
Extracellular glutamate is taken up into intracellular locations
through particular EAAT isoforms that are functionally expressed
by rodent chondrocytes66. In the connective tissues, glutamate
receptors and transporters are expressed in chondrocytes40,66,
osteoblasts67, osteocytes67, osteoclasts67, keratinocytes68, and
ﬁbroblasts69,70. Under physiological conditions, serum glutamate
levels vary from a low micromolar range in humans71 to a high
micromolar range in rats72. The concentration of glutamate in
plasma is 300 mM, which is greater than the reported ED50 for
peripheral glutamate receptor activation73e75. Glutamate cytotox-
icity is only evident at a high concentration of 10 mM3.
GLAST and GLT-1 are expressed in osteoblasts and osteocytes
in vivo76, while EAAT3 has been detected in rat primary osteoblasts
in vitro77. In contrast, EAAT2 and EAAT4 appear to be the predom-
inant EAATs in osteoclasts78. Genever et al. previously reported that
osteoblasts express GLAST and rapidly accumulate [3H]-glutamate;
this suggests the molecular mechanism for intracellular glutamate
accumulation3. An immunohistochemical analysis reveals the
constitutive expression of GLAST in both osteoblasts and osteocytes
and of GLT-1 in mononuclear bone marrow cells5. Our previous
study found increased GLAST and GLT-1 expression in cartilage
specimens from rabbits 30 weeks after ACLT79. Mason et al.80 re-
ported that glutamate receptors and transporters are highly
expressed in the subchondral bone of patients with OA of the knee,
and that EAAT1 expression may vary among anatomical locations
and pathologies and suggested that activation of these receptors
and transporters by the increased synovial glutamate concentra-
tion that occurs in OA may contribute to OA development and pain.tes
oblast Osteoclast Osteocyte Chondrocyte
, NR2D NR1, NR1 NR,NR2B*
NR2A~NR2D NR2D
GluR5, R6, R7
1, R2 GluR1~R4 GluR1, R2 GluR2
mGluR8
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CNS81,82, glutamate liberated from cartilage is not actively trans-
ported by the same reuptake systems. Therefore, the clearance of
extracellular glutamate from the periarticular regions would be
slower than that from the CNS, and concentrations of extracellular
free glutamate could persist. Furthermore, understanding the role
of glutamate and the regulation of its uptake in animal models of
OA and the importance of selective microenvironments will be
helpful for elucidating the mechanisms underlying the pathogen-
esis of OA and developing new therapeutic strategies.
VGLUTs
Within the CNS, VGLUTs are essential for signal output through
the condensation of glutamate into vesicular constituents for sub-
sequent exocytotic release upon stimulation. VGLUT183 and
VGLUT284 isoforms deﬁne glutamatergic phenotypes in different
endocrine and neurocrine cells85,86. VGLUT3 is expressed in a
number of cells that release glutamate through exocytosis
including GABAergic, dopaminergic, and serotonergic neurons as
well as astrocytes87. VGLUT-1 knockout mice develop osteoporosis
due to increased bone resorption26. In our laboratory, we found
VGLUT-1 and VGLUT-2 protein expression in the cartilage, syno-
vium, and meniscus of naïve and ACLT Wistar rat knees. This
ﬁnding may suggest that the cartilage, synovium, and meniscus
may release glutamate induced by ACLT.Glutamate
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Fig. 1. Working model of the expression and function of glutamatergic signaling mechan
transporters are essential for signal termination, and VGLUTs are essential for signal outp
exocytotic release. Glutamate is converted into glutamine by the enzyme glutamine synthaCystine/glutamate antiporter
The cystine/glutamate antiporter system Xc (system Xc) is a
bidirectional transporter that performs exocytosis for glutamate
and endocytosis for cystine and functions as the rate-limiting factor
in antioxidant glutathione synthesis88. High glutamate concentra-
tions were shown to lead chondrocyte apoptosis by modulating
system Xc89. System Xc is the rate-limiting step in the synthesis of
glutathione88,90, which protects chondrocytes against oxidative
stress during OA development91,92. Reports have demonstrated the
involvement of the cystine/glutamate antiporter in the mecha-
nisms underlying osteoclastogenesis78 as well as osteoblasto-
genesis80 associated with bone remodeling. EAATs are not only
required for the termination of glutamatergic signaling but are
needed for preventing the inhibition of the cystine/glutamate
antiporter Xc93. System Xc is composed of the structural subunit of
CD98 (also called 4F2hc) and the functional subunit of xCT, both of
which are found in chondrocytes and are shown to mediate
glutamate-induced chondrocyte apoptosis during the development
of the metatarsal bones of the foot89,94. In our previous reports,
early intra-articular injection of hyaluronic acid not only attenuated
the progression of cartilage destruction in the OA rat knee but also
downregulated the cystine/glutamate antiporter system Xc and
was accompanied by the progression of OA91. A Working model of
the expression and function of glutamatergic signalingmechanisms
in the knee joint is shown in Fig. 1.tamine
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Glutamatergic mechanisms are implicated in acute and chronic
pain, and a great diversity of glutamate receptors can be used as
targets for analgesics. While an extensive preclinical literature ex-
ists showing potential beneﬁcial effects of NMDA-, AMPA-, kainite-
and metabotropic receptor ligands, only NMDA receptor antago-
nists have been characterized clinically to any appreciable degree. A
number of drugs have been developed and introduced in clinics.
Examples include memantine95,96 (in dementia and Parkinson's
disease), Riluzole97e99 (in amyotrophic lateral sclerosis, and as an
anticonvulsant and a sedative), and ketamine100,101 (in pain and as a
general anesthetic). The importance of glutamate in arthritis is
further highlighted using rodent arthritis models, as inhibition of
NMDA with memantine delayed the onset of collagen-induced
arthritis and reduced bone resorption in mice49. In antigen-
induced arthritis in rats, Boettger et al.100 showed that intrathecal
administration of the uncompetitive NMDA receptor channel
blocker, ketamine, reduced the pain and severity of arthritis. The
response was characterized by reduced joint swelling and
decreased inﬁltration of inﬂammatory cells into the joint cavity. A
Phase II trial of an iGluR5 antagonist, LY545694, in the treatment of
knee OA pain has been completed102.
Several more years of research will probably be required before
one can reasonably assess whether ligands for NMDA, AMPA, KA, or
metabotropic receptors are therapeutically active and safe drugs. As
will be evident from the present review article, hopes are high and
preclinical data are accumulating that drugs acting on different
glutamate receptorsmaybebeneﬁcial in a largevarietyofOAdisease
states. Glutamate antagonists, which are tolerated in humans, and
which do not cross the bloodebrain barrier, are a timely potential
therapeutic for modulating glutamatergic signaling in joints to
treat OA.
Conclusion
Evaluation of glutamate signaling and its strict regulation could
be of great beneﬁt for the future elucidation of molecular mecha-
nisms of arthritis, such as OA. This review discussed the differential
role of glutamate signaling in regulating bone remodeling systems
and joint tissues as well as the possible roles of glutamate in the
inﬂammatory processes associated with OA. We also reviewed
several novel glutamate-based therapies that impacted the devel-
opment of experimental OA structural and nociceptive changes.
Future studies are needed to elucidate the role of glutamate and
glutamate receptor activation and potential blockade in their as-
sociations with the different clinical features of the disease.
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